

# Siddesh V Hartimath

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6342429/publications.pdf>

Version: 2024-02-01

15  
papers

212  
citations

1040056

9  
h-index

996975

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung endothelial cell antigen cross-presentation to CD8+T cells drives malaria-associated lung injury. <i>Nature Communications</i> , 2019, 10, 4241.	12.8	36
2	[ <sup>99m</sup> Tc]O <sub>2</sub> -AMD3100 as a SPECT tracer for CXCR4 receptor imaging. <i>Nuclear Medicine and Biology</i> , 2013, 40, 507-517.	0.6	26
3	<sup>111</sup> In- and <sup>225</sup> Ac-Labeled Cixutumumab for Imaging and $\beta$ -Particle Radiotherapy of IGF-1R Positive Triple-Negative Breast Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 4807-4816.	4.6	23
4	Preclinical Evaluation of <sup>111</sup> In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1103-1110.	5.0	22
5	Examining Immunotherapy Response Using Multiple Radiotracers. <i>Molecular Imaging and Biology</i> , 2020, 22, 993-1002.	2.6	16
6	Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer. <i>Molecular Imaging and Biology</i> , 2021, 23, 714-723.	2.6	16
7	Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft. <i>Oncotarget</i> , 2019, 10, 1031-1044.	1.8	14
8	Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study. <i>Oncotarget</i> , 2018, 9, 7162-7174.	1.8	13
9	<sup>99m</sup> Tc(CO) <sub>3</sub> + labeled domain I/II-specific anti-EGFR (scFv) <sub>2</sub> antibody fragment for imaging EGFR expression. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 437-446.	5.5	11
10	Dopamine transporter neuroimaging accurately assesses the maturation of dopamine neurons in a preclinical model of Parkinson's disease. <i>Stem Cell Research and Therapy</i> , 2020, 11, 347.	5.5	8
11	<sup>111</sup> In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft Model. <i>Molecular Pharmaceutics</i> , 2019, 16, 542-551.	4.6	7
12	Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer. <i>Scientific Reports</i> , 2020, 10, 18549.	3.3	7
13	Longitudinal [ <sup>18</sup> F]FB-IL-2 PET Imaging to Assess the Immunopathogenicity of O'nyong-nyong Virus Infection. <i>Frontiers in Immunology</i> , 2020, 11, 894.	4.8	5
14	PET Imaging of Translocator Protein as a Marker of Malaria-Associated Lung Inflammation. <i>Infection and Immunity</i> , 2021, 89, e0002421.	2.2	4
15	An Improved Synthesis of N-(4-[ <sup>18</sup> F]Fluorobenzoyl)-Interleukin-2 for the Preclinical PET Imaging of Tumour-Infiltrating T-cells in CT26 and MC38 Colon Cancer Models. <i>Molecules</i> , 2021, 26, 1728.	3.8	3